# Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

Source: https://onco.cc/trials/nct07724223/  
OnCo record `nct07724223` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fruquintinib and cetuximab in colorectal cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.

## Summary

Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC is a phase 2, interventional study registered as NCT07724223 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 46 participants, started 2026-01-16 and due to reach its primary completion in 2028-10-01. Interventions recorded: Fruquintinib plus Cetuximab-beta. Conditions listed: Metastatic Colorectal Cancer (CRC). Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: "Histologically confirmed metastatic or advanced colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07724223
- Phase: 2
- Setting: A Phase II Study of Fruquintinib Combined With Anti-EGFR Monoclonal Antibody in Third-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer
- Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT07724223: https://clinicaltrials.gov/study/NCT07724223

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07724223.json